Liposomal bupivacaine in lower extremity arthroplasty: a comprehensive review - Scorecard - MDSpire

Liposomal bupivacaine in lower extremity arthroplasty: a comprehensive review

  • By

  • Fang, Yuang

  • Hu, Beilin

  • Mu, Guo

  • Yu, Hong

  • Zhou, Jun

  • April 6, 2026

Share

Clinical Scorecard: A Thorough Examination of Liposomal Bupivacaine for Pain Management in Lower Limb Joint Replacement Surgery

At a Glance

CategoryDetail
Condition
Key MechanismsLiposomal bupivacaine provides sustained analgesia for up to 72 hours. [Source needed]
Target Population
Care Setting

Key Highlights

  • Liposomal bupivacaine reduces 24-hour opioid requirements by 35-50%. [Source needed]
  • Decreases hospital length of stay by an average of 0.5 days. [Source needed]
  • Enhances early-phase analgesia with a mean difference of -1.2 points on VAS at 24 hours. [Source needed]
  • Particularly effective when used with adductor canal block in TKA procedures. [Source needed]
  • Cost-effectiveness varies by surgical procedure. [Source needed]

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider liposomal bupivacaine for postoperative pain management in lower limb joint replacement surgery. [Source needed]

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Liposomal bupivacaine provides significant opioid-sparing effects and enhances recovery. [Source needed]

        Clinical Best Practices

        • Utilize liposomal bupivacaine in conjunction with regional anesthesia techniques. [Source needed]
        • Assess cost-benefit profile of liposomal bupivacaine based on surgical procedure. [Source needed]

        Related Resources & Content

        Original Source(s)

        Liposomal bupivacaine in lower extremity arthroplasty: a comprehensive review

        • by Fang, Yuang , Hu, Beilin , Mu, Guo , Yu, Hong , Zhou, Jun

        • April 6, 2026

        Related Content

        Only a partial shield: local vancomycin postpones but does not prevent hip and knee prosthetic infections

        CAA Use Tied to Higher Arthroplasty Risk

        In a UK cohort, patients with osteoarthritis who initiated centrally acting analgesics had a higher hazard of knee or hip replacement than those who initiated SSRIs, though residual confounding by pain severity remains a key limitation.

        Cross-Linked HA Did Not Outperform Saline

        Two single-injection cross-linked hyaluronic acid formulations showed no statistically significant advantage over saline for pain or functional outcomes through 24 weeks.